LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a new clinical case study ...
A Global Grand Challenges case study reveals the potential of large language models (LLMs) to close health gaps in South Asia ...
German company MVZ Medizinische Labore Dessau Kassel GmbH (MVZ) has positioned itself as an industry leader in the development of rapid, sensitive means of testing for drugs of abuse using capillary ...
Details of Cresilon's presentation are as follows: ...
A peripheral IV was placed, and the patient was connected to a cardiac monitor, which showed atrial fibrillation and a heart rate of 70 beats/minute, which is a rare presentation but could be ...
Over the past 25 years, a Canadian medical journal has been publishing fictional clinical case reports but framing them as ...
The Canadian case study posters featured four unique clinical cases, part of a larger series, observing changes in wound size, pain, exudate, and tissue regranulation over time in patients with ...
SAN ANTONIO, Texas--(BUSINESS WIRE)--$BIAF #BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results